LAIR-1 Limits Neutrophilic Airway Inflammation
Neutrophils are crucial to antimicrobial defense, but excessive neutrophilic inflammation induces immune pathology. The mechanisms by which neutrophils are regulated to prevent injury and preserve tissue homeostasis are not completely understood. We recently identified the collagen receptor leukocyt...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00842/full |
id |
doaj-68d3e6aaec414ebcb1893ff0140bd63d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kuldeep Kumawat Kuldeep Kumawat Ruben J. Geerdink Ruben J. Geerdink Marije P. Hennus Mojtaba Abdul Roda Ingrid van Ark Thea Leusink-Muis Gert Folkerts Anita van Oort-Jansen Alexandra Mazharian Steve P. Watson Steve P. Watson Frank E. Coenjaerts Louis Bont Louis Bont Linde Meyaard Linde Meyaard |
spellingShingle |
Kuldeep Kumawat Kuldeep Kumawat Ruben J. Geerdink Ruben J. Geerdink Marije P. Hennus Mojtaba Abdul Roda Ingrid van Ark Thea Leusink-Muis Gert Folkerts Anita van Oort-Jansen Alexandra Mazharian Steve P. Watson Steve P. Watson Frank E. Coenjaerts Louis Bont Louis Bont Linde Meyaard Linde Meyaard LAIR-1 Limits Neutrophilic Airway Inflammation Frontiers in Immunology LAIR-1 neutrophils RSV airway inflammation bronchiolitis |
author_facet |
Kuldeep Kumawat Kuldeep Kumawat Ruben J. Geerdink Ruben J. Geerdink Marije P. Hennus Mojtaba Abdul Roda Ingrid van Ark Thea Leusink-Muis Gert Folkerts Anita van Oort-Jansen Alexandra Mazharian Steve P. Watson Steve P. Watson Frank E. Coenjaerts Louis Bont Louis Bont Linde Meyaard Linde Meyaard |
author_sort |
Kuldeep Kumawat |
title |
LAIR-1 Limits Neutrophilic Airway Inflammation |
title_short |
LAIR-1 Limits Neutrophilic Airway Inflammation |
title_full |
LAIR-1 Limits Neutrophilic Airway Inflammation |
title_fullStr |
LAIR-1 Limits Neutrophilic Airway Inflammation |
title_full_unstemmed |
LAIR-1 Limits Neutrophilic Airway Inflammation |
title_sort |
lair-1 limits neutrophilic airway inflammation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-04-01 |
description |
Neutrophils are crucial to antimicrobial defense, but excessive neutrophilic inflammation induces immune pathology. The mechanisms by which neutrophils are regulated to prevent injury and preserve tissue homeostasis are not completely understood. We recently identified the collagen receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1 as a functional inhibitory receptor on airway-infiltrated neutrophils in viral bronchiolitis patients. In the current study, we sought to examine the role of LAIR-1 in regulating airway neutrophil responses in vivo. LAIR-1-deficient (Lair1−/−) and wild-type mice were infected with respiratory syncytial virus (RSV) or exposed to cigarette smoke as commonly accepted models of neutrophil-driven lung inflammation. Mice were monitored for cellular airway influx, weight loss, cytokine production, and viral loads. After RSV infection, Lair1−/− mice show enhanced airway inflammation accompanied by increased neutrophil and lymphocyte recruitment to the airways, without effects on viral loads or cytokine production. LAIR-1-Fc administration in wild type mice, which blocks ligand induced LAIR-1 activation, augmented airway inflammation recapitulating the observations in Lair1−/− mice. Likewise, in the smoke-exposure model, LAIR-1 deficiency enhanced neutrophil recruitment to the airways and worsened disease severity. Intranasal CXCL1–mediated neutrophil recruitment to the airways was enhanced in mice lacking LAIR-1, supporting an intrinsic function of LAIR-1 on neutrophils. In conclusion, the immune inhibitory receptor LAIR-1 suppresses neutrophil tissue migration and acts as a negative regulator of neutrophil-driven airway inflammation during lung diseases. Following our recent observations in humans, this study provides crucial in-vivo evidence that LAIR-1 is a promising target for pharmacological intervention in such pathologies. |
topic |
LAIR-1 neutrophils RSV airway inflammation bronchiolitis |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.00842/full |
work_keys_str_mv |
AT kuldeepkumawat lair1limitsneutrophilicairwayinflammation AT kuldeepkumawat lair1limitsneutrophilicairwayinflammation AT rubenjgeerdink lair1limitsneutrophilicairwayinflammation AT rubenjgeerdink lair1limitsneutrophilicairwayinflammation AT marijephennus lair1limitsneutrophilicairwayinflammation AT mojtabaabdulroda lair1limitsneutrophilicairwayinflammation AT ingridvanark lair1limitsneutrophilicairwayinflammation AT thealeusinkmuis lair1limitsneutrophilicairwayinflammation AT gertfolkerts lair1limitsneutrophilicairwayinflammation AT anitavanoortjansen lair1limitsneutrophilicairwayinflammation AT alexandramazharian lair1limitsneutrophilicairwayinflammation AT stevepwatson lair1limitsneutrophilicairwayinflammation AT stevepwatson lair1limitsneutrophilicairwayinflammation AT frankecoenjaerts lair1limitsneutrophilicairwayinflammation AT louisbont lair1limitsneutrophilicairwayinflammation AT louisbont lair1limitsneutrophilicairwayinflammation AT lindemeyaard lair1limitsneutrophilicairwayinflammation AT lindemeyaard lair1limitsneutrophilicairwayinflammation |
_version_ |
1724971294902976512 |
spelling |
doaj-68d3e6aaec414ebcb1893ff0140bd63d2020-11-25T01:57:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-04-011010.3389/fimmu.2019.00842446190LAIR-1 Limits Neutrophilic Airway InflammationKuldeep Kumawat0Kuldeep Kumawat1Ruben J. Geerdink2Ruben J. Geerdink3Marije P. Hennus4Mojtaba Abdul Roda5Ingrid van Ark6Thea Leusink-Muis7Gert Folkerts8Anita van Oort-Jansen9Alexandra Mazharian10Steve P. Watson11Steve P. Watson12Frank E. Coenjaerts13Louis Bont14Louis Bont15Linde Meyaard16Linde Meyaard17Laboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, NetherlandsOncode Institute, University Medical Center Utrecht, Utrecht, NetherlandsLaboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, NetherlandsOncode Institute, University Medical Center Utrecht, Utrecht, NetherlandsDepartment of Pediatric Intensive Care, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, NetherlandsDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NetherlandsDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NetherlandsDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NetherlandsDivision of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, NetherlandsLaboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, NetherlandsCentre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United KingdomCentre for Cardiovascular Sciences, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United KingdomCentre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, Birmingham, United KingdomDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, NetherlandsLaboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, NetherlandsDepartment of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, NetherlandsLaboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht, NetherlandsOncode Institute, University Medical Center Utrecht, Utrecht, NetherlandsNeutrophils are crucial to antimicrobial defense, but excessive neutrophilic inflammation induces immune pathology. The mechanisms by which neutrophils are regulated to prevent injury and preserve tissue homeostasis are not completely understood. We recently identified the collagen receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1 as a functional inhibitory receptor on airway-infiltrated neutrophils in viral bronchiolitis patients. In the current study, we sought to examine the role of LAIR-1 in regulating airway neutrophil responses in vivo. LAIR-1-deficient (Lair1−/−) and wild-type mice were infected with respiratory syncytial virus (RSV) or exposed to cigarette smoke as commonly accepted models of neutrophil-driven lung inflammation. Mice were monitored for cellular airway influx, weight loss, cytokine production, and viral loads. After RSV infection, Lair1−/− mice show enhanced airway inflammation accompanied by increased neutrophil and lymphocyte recruitment to the airways, without effects on viral loads or cytokine production. LAIR-1-Fc administration in wild type mice, which blocks ligand induced LAIR-1 activation, augmented airway inflammation recapitulating the observations in Lair1−/− mice. Likewise, in the smoke-exposure model, LAIR-1 deficiency enhanced neutrophil recruitment to the airways and worsened disease severity. Intranasal CXCL1–mediated neutrophil recruitment to the airways was enhanced in mice lacking LAIR-1, supporting an intrinsic function of LAIR-1 on neutrophils. In conclusion, the immune inhibitory receptor LAIR-1 suppresses neutrophil tissue migration and acts as a negative regulator of neutrophil-driven airway inflammation during lung diseases. Following our recent observations in humans, this study provides crucial in-vivo evidence that LAIR-1 is a promising target for pharmacological intervention in such pathologies.https://www.frontiersin.org/article/10.3389/fimmu.2019.00842/fullLAIR-1neutrophilsRSVairwayinflammationbronchiolitis |